You may find more results for this query on our sister sites: GenomeWeb and 360Dx.
News and reporting on BRCA biomarkers.
Researchers reclassified 86 percent of variants initially determined to be VUS, potentially changing surveillance or treatment approaches for patients.
According to a biomarker analysis from a Phase II trial, cediranib plus olaparib improved progression-free survival versus olaparib in HRR-deficient mCRPC.
Two new studies revealed the prevalence of pathogenic variants in breast cancer-related genes, while highlighting genes that may be most informative in the clinic.
The Japanese Ministry of Health, Labor, and Welfare approved the molecularly defined indications based on data from the PAOLA-1, PROfound, and POLO trials.
The PARP inhibitor was found to be most cost-effective as a maintenance treatment for those with a BRCA1 mutation and who receive chemo for more than six months.
An exploratory analysis in the ASCENT study showed improved survival with Gilead's antibody-drug conjugate regardless of patients' biomarker status.
A case series in partnership with My Gene Counsel to highlight the challenges genetics professionals and oncologists are grappling with as genetic testing is increasingly used in patient care.
Researchers found that cancer patients with BRCA2 mutations respond particularly well to checkpoint inhibitors compared to those with BRCA1 mutations.
Regulators approved the PARP inhibitor as a monotherapy for BRCA1/2-mutated mCRPC and together with Avastin for advanced, HRD-positive ovarian cancer.
The recently launched BRCA Care program may increase test access in six countries, though it cannot ensure access to downstream interventions based on results.